UK-based Alchemab expanded its Series A financing round by $32 million, bringing the total to $114 million to advance its AI-driven antibody discovery platform. The funding will support first-in-human clinical testing of ATLX-1282, a broadly neuroprotective antibody candidate licensed exclusively by Eli Lilly. Additionally, Alchemab advances ATLX-2847 in clinical trials targeting muscle atrophy via prostaglandin pathway modulation. CEO Jane Osbourn highlighted partnerships focusing on immunology and strategies to identify complementary pharma collaborators. The extended finances provide a three-year runway enabling milestone achievements across multiple wholly owned and partnered programs.